Patient characteristics
. | HLA-identical siblings . | VUDs . | Total . | P . |
|---|---|---|---|---|
| Source of donor (%) | 182 (58) | 132 (42) | 314 (100) | |
| Stage of CML at SCT | .007 | |||
| CP1 (%) | 156 (85.7) | 97 (73.5) | 253 (80.6) | |
| AP (%) | 26 (14.3) | 35 (26.5) | 61 (19.4) | |
| Median recipient age at SCT, y (range) | 14 (0-17) | 14 (1-17) | 14 (0-17) | NS |
| Median donor age, y (range) | 13 (0-33) | 33 (8-59) | 18 (0-59) | < .001 |
| Missing | 26 | 51 | 77 | |
| Interval from diagnosis to SCT | < .001 | |||
| 0-6 mo (%) | 81 (44.5) | 19 (14.4) | 100 (31.8) | |
| 6-12 mo (%) | 49 (26.9) | 40 (30.3) | 89 (28.3) | |
| 12 mo or longer (%) | 52 (28.6) | 73 (55.3) | 125 (39.8) | |
| Date of SCT | < .001 | |||
| SCT performed before 1995 (%) | 118 (64.8) | 46 (34.8) | 164 (52.2) | |
| SCT performed 1995 or later (%) | 64 (35.2) | 86 (65.2) | 150 (47.8) | |
| Sex combination: R/D | NS | |||
| Male recipient/female donor (%) | 49 (26.9) | 30 (22.7) | 79 (25.2) | |
| Other sex combinations (%) | 133 (73.1) | 102 (77.3) | 235 (74.8) | |
| Conditioning regimen: TBI- | < .001 | |||
| Yes (%) | 99 (54.4) | 115 (87.1) | 214 (68.2) | |
| No (%) | 83 (45.6) | 17 (12.9) | 100 (31.8) | |
| GVHD prophylaxis | < .001 | |||
| TCD +/- CSA, MTX (%) | 26 (14) | 81 (61) | 107 (34) | |
| CSA alone (%) | 54 (30) | 1 (1) | 55 (18) | |
| CSA + MTX (%) | 102 (56) | 50 (38) | 152 (48) | |
| CMV status: R/D* | .008 | |||
| -/- (%) | 57 (36.5) | 45 (37.2) | 102 (36.8) | |
| -/+ (%) | 14 (9) | 27 (22.3) | 41 (14.8) | |
| +/- (%) | 26 (16.7) | 11 (9.1) | 37 (13.4) | |
| +/+ (%) | 59 (37.8) | 38 (31.4) | 97 (35) | |
| Missing | 26 | 11 | 37 | |
| IFN before SCT* | < .001 | |||
| Yes (%) | 39 (24.1) | 59 (54.6) | 98 (36.3) | |
| No (%) | 123 (75.9) | 49 (45.4) | 172 (63.7) | |
| Missing | 20 | 24 | 44 |
. | HLA-identical siblings . | VUDs . | Total . | P . |
|---|---|---|---|---|
| Source of donor (%) | 182 (58) | 132 (42) | 314 (100) | |
| Stage of CML at SCT | .007 | |||
| CP1 (%) | 156 (85.7) | 97 (73.5) | 253 (80.6) | |
| AP (%) | 26 (14.3) | 35 (26.5) | 61 (19.4) | |
| Median recipient age at SCT, y (range) | 14 (0-17) | 14 (1-17) | 14 (0-17) | NS |
| Median donor age, y (range) | 13 (0-33) | 33 (8-59) | 18 (0-59) | < .001 |
| Missing | 26 | 51 | 77 | |
| Interval from diagnosis to SCT | < .001 | |||
| 0-6 mo (%) | 81 (44.5) | 19 (14.4) | 100 (31.8) | |
| 6-12 mo (%) | 49 (26.9) | 40 (30.3) | 89 (28.3) | |
| 12 mo or longer (%) | 52 (28.6) | 73 (55.3) | 125 (39.8) | |
| Date of SCT | < .001 | |||
| SCT performed before 1995 (%) | 118 (64.8) | 46 (34.8) | 164 (52.2) | |
| SCT performed 1995 or later (%) | 64 (35.2) | 86 (65.2) | 150 (47.8) | |
| Sex combination: R/D | NS | |||
| Male recipient/female donor (%) | 49 (26.9) | 30 (22.7) | 79 (25.2) | |
| Other sex combinations (%) | 133 (73.1) | 102 (77.3) | 235 (74.8) | |
| Conditioning regimen: TBI- | < .001 | |||
| Yes (%) | 99 (54.4) | 115 (87.1) | 214 (68.2) | |
| No (%) | 83 (45.6) | 17 (12.9) | 100 (31.8) | |
| GVHD prophylaxis | < .001 | |||
| TCD +/- CSA, MTX (%) | 26 (14) | 81 (61) | 107 (34) | |
| CSA alone (%) | 54 (30) | 1 (1) | 55 (18) | |
| CSA + MTX (%) | 102 (56) | 50 (38) | 152 (48) | |
| CMV status: R/D* | .008 | |||
| -/- (%) | 57 (36.5) | 45 (37.2) | 102 (36.8) | |
| -/+ (%) | 14 (9) | 27 (22.3) | 41 (14.8) | |
| +/- (%) | 26 (16.7) | 11 (9.1) | 37 (13.4) | |
| +/+ (%) | 59 (37.8) | 38 (31.4) | 97 (35) | |
| Missing | 26 | 11 | 37 | |
| IFN before SCT* | < .001 | |||
| Yes (%) | 39 (24.1) | 59 (54.6) | 98 (36.3) | |
| No (%) | 123 (75.9) | 49 (45.4) | 172 (63.7) | |
| Missing | 20 | 24 | 44 |
AP indicates advanced phase (accelerated phase, BC, CP2); MTX, methotrexate; and NS, statistically nonsignificant.
Percentages calculated for patients for whom data were available.